WO2002022657A3 - Peptide antagonist of multiple chemokine receptors and uses thereof - Google Patents

Peptide antagonist of multiple chemokine receptors and uses thereof Download PDF

Info

Publication number
WO2002022657A3
WO2002022657A3 PCT/CA2001/001265 CA0101265W WO0222657A3 WO 2002022657 A3 WO2002022657 A3 WO 2002022657A3 CA 0101265 W CA0101265 W CA 0101265W WO 0222657 A3 WO0222657 A3 WO 0222657A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
antagonist
peptide antagonist
chemokine receptors
reduction
Prior art date
Application number
PCT/CA2001/001265
Other languages
French (fr)
Other versions
WO2002022657A2 (en
Inventor
Ian Clark-Lewis
Jiang-Hong Gong
Pius Loetscher
Original Assignee
Univ British Columbia
Ian Clark-Lewis
Jiang-Hong Gong
Pius Loetscher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia, Ian Clark-Lewis, Jiang-Hong Gong, Pius Loetscher filed Critical Univ British Columbia
Priority to AU2001287463A priority Critical patent/AU2001287463A1/en
Publication of WO2002022657A2 publication Critical patent/WO2002022657A2/en
Publication of WO2002022657A3 publication Critical patent/WO2002022657A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

The present invention provides a peptide, with the structure of Formula (I), having antagonist activity toward multiple chemokine receptors: NH2-F P M F K R G R - X wherein X is: C; K; a covalent linker; C* --- C* R G R K F M P F - NH2, wherein C* --- C* represents a disulphide bridge; K - R G R K F M P F - NH2, wherein K - R represents an amide bond between the ε-amino group of K and the carboxyl group of R; or a covalent linker additionally bound to a second NH2 - F P M F K R G R at its C- terminal R, and wherein NH2 represents the N-terminus. The present invention also teaches methods for the production and testing of the peptide antagonist, in addition to methods of chemically modifying the peptide of Formula (I) to enhance bioavailability and/or activity. Also provided is a therapeutic method comprising administration of the peptide antagonist to a patient in need of a reduction of chemokine receptor(s) function in the treatment of inflammatory diseases or disorders or for the prevention or reduction of HIV infection.
PCT/CA2001/001265 2000-09-12 2001-09-12 Peptide antagonist of multiple chemokine receptors and uses thereof WO2002022657A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001287463A AU2001287463A1 (en) 2000-09-12 2001-09-12 Peptide antagonist of multiple chemokine receptors and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2318006 2000-09-12
CA2,318,006 2000-09-12

Publications (2)

Publication Number Publication Date
WO2002022657A2 WO2002022657A2 (en) 2002-03-21
WO2002022657A3 true WO2002022657A3 (en) 2002-10-03

Family

ID=4167084

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2001/001265 WO2002022657A2 (en) 2000-09-12 2001-09-12 Peptide antagonist of multiple chemokine receptors and uses thereof

Country Status (2)

Country Link
AU (1) AU2001287463A1 (en)
WO (1) WO2002022657A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104892744B (en) * 2015-01-26 2020-01-31 徐岩 active polypeptide with antagonistic chemokine receptor CXCR4, design and preparation thereof and biomedical application

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047158A2 (en) * 1998-03-13 1999-09-23 The University Of British Columbia Therapeutic chemokine receptor antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047158A2 (en) * 1998-03-13 1999-09-23 The University Of British Columbia Therapeutic chemokine receptor antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LOETSCHER ET AL: "N-TERMINAL PEPTIDES OF STROMAL CELL-DERIVED FACTOR WITH CXC CHEMOKINE RECEPTOR 4 AGONIST AND ANTAGONIST ACTIVITIES", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 273, no. 35, 28 August 1998 (1998-08-28), pages 22279 - 22283, XP002115696, ISSN: 0021-9258 *
NISHIYAMA YASUHIRO ET AL: "Low-molecular-weight anti-HIV-1 peptides from the amino-terminal sequence of RANTES: Possible lead compounds for coreceptor-directed anti-HIV-1 agents.", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 9, no. 10, 17 May 1999 (1999-05-17), pages 1357 - 1360, XP002203606, ISSN: 0960-894X *

Also Published As

Publication number Publication date
AU2001287463A1 (en) 2002-03-26
WO2002022657A2 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
WO2004110472A3 (en) Fusion proteins
WO2002002525A3 (en) N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
WO2003024401A3 (en) Piperizinones as modulators of chemokine receptor activity
TR200101859T2 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2001098268A3 (en) Piperidine amides as modulators of chemokine receptor activity
CA2380569A1 (en) Chimeric polypeptides, method for production and uses thereof
ATE284413T1 (en) THERAPEUTIC PEPTIDE DERIVATIVES
TR200202253T2 (en) Recombinant IL-18 antagonists useful in the treatment of IL-18 induced disorders
AU3126600A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP2311871A3 (en) IL-1 antagonist stable liquid formulation
WO2002043746A3 (en) Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
WO2001028987A8 (en) Benzylcycloalkyl amines as modulators of chemokine receptor activity
UA91820C2 (en) Therapeutic uses of chemokine variants
DE69221486D1 (en) BOMBESIN ANALOG
EP1452543A3 (en) RGD (ARG-GLY-ASP) coupled to (neuro)peptides
WO2001098270A3 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO1997010824A8 (en) Use of 5ht1b receptor antagonist for the treatment of vascular disease
ATE481420T1 (en) IL-21 DERIVATIVES
WO2001005811A3 (en) Cyclic peptidomimetic urokinase receptor antagonists
WO2001036656A3 (en) A complex between hyaluronic acid and a biomolecule and its use
WO2002022657A3 (en) Peptide antagonist of multiple chemokine receptors and uses thereof
ATE370160T1 (en) PEPTIDES HAVING AFFINITY FOR GP120, AND USES THEREOF
WO2002044384A3 (en) T-cell epitope of the papillomavirus l1 and e7 protein and use thereof in diagnostics and therapy
WO2002007676A3 (en) Compounds having affinity for the granulocyte-colony stimulating factor receptor (g-csfr)
WO2001010893A3 (en) Il-16 antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP